Sélection de la langue

Gouvernement du Canada / Government of Canada

Recherche

Toxin-specific antibodies and antibody fragments for the treatment of Clostridium difficile. Current status and future prospectives

Par Conseil national de recherches du Canada

DOITrouver le DOI : https://doi.org/10.3390/toxins2050998
AuteurRechercher : 1; Rechercher : 1
Affiliation
  1. Conseil national de recherches du Canada. Institut des sciences biologiques du CNRC
FormatTexte, Article
SujetClostridium difficile; Clostridium difficile-associated disease; toxin; antibody; single-domain antibody; neutralization; therapy
Résumé
Therapeutic agents targeting bacterial virulence factors are gaining interest as non-antibiotic alternatives for the treatment of infectious diseases. Clostridium difficile is a Gram-positive pathogen that produces two primary virulence factors, enterotoxins A and B (TcdA and TcdB), which are responsible for Clostridium difficile-associated disease (CDAD) and are targets for CDAD therapy. Antibodies specific for TcdA and TcdB have been shown to effectively treat CDAD and prevent disease relapse in animal models and in humans. This review summarizes the various toxin-specific antibody formats and strategies under development, and discusses future directions for CDAD immunotherapy, including the use of engineered antibody fragments with robust biophysical properties for systemic and oral delivery.
Date de publication
Dans
  • Toxins 5, nº 2 (7 mai 2010) : 998–1018.
Langueanglais
Publications évaluées par des pairsOui
Numéro NPARC17401055
Exporter la noticeExporter en format RIS
Signaler une correctionSignaler une correction (s'ouvre dans un nouvel onglet)
Identificateur de l’enregistremente619d5d8-6fe6-45e0-a202-030e016ad2c6
Enregistrement créé2011-03-25
Enregistrement modifié2020-04-17
Date de modification :